Moderna, Inc. Finance Lease, Right-of-Use Asset, after Accumulated Amortization
Moderna, Inc. (MRNA) had Finance Lease, Right-of-Use Asset, after Accumulated Amortization of $30.00 million as of 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:FinanceLeaseRightOfUseAsset · last filed 2026-07-31
- 2026-06-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $30.00M.
- 2026-03-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $36.00M.
- 2025-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $42.00M.
- 2025-09-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $47.00M.
| Period end | Finance Lease, Right-of-Use Asset, after Accumulated Amortization | Finance Lease, Right-of-Use Asset, after Accumulated Amortization as first filed |
|---|---|---|
| 2026-06-30 | $30.00M 10-Q · filed 2026-07-31 | |
| 2026-03-31 | $36.00M 10-Q · filed 2026-05-01 | |
| 2025-12-31 | $42.00M 10-Q · filed 2026-07-31 | |
| 2025-09-30 | $47.00M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $53.00M 10-Q · filed 2025-08-01 | |
| 2025-03-31 | $59.00M 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $65.00M 10-K · filed 2026-02-20 | |
| 2024-09-30 | $498.00M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $430.00M 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $433.00M 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $436.00M 10-K · filed 2025-02-21 | |
| 2023-09-30 | $601.00M 10-Q · filed 2023-11-03 | |
| 2023-06-30 | $1.08B 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $1.03B 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $1.15B 10-K · filed 2024-02-23 | |
| 2022-09-30 | $1.21B 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $619.00M 10-Q · filed 2022-08-03 | |
| 2022-03-31 | $693.00M 10-Q · filed 2022-05-04 | |
| 2021-12-31 | $665.00M 10-K · filed 2023-02-24 | |
| 2021-09-30 | $416.00M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $475.00M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $99.00M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $55.00M 10-K · filed 2022-02-25 | $55.05M 10-K · filed 2021-02-26 |
| 2020-09-30 | $55.50M 10-Q · filed 2020-10-30 | |
| 2020-06-30 | $23.70M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $9.49M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $9.54M 10-K · filed 2021-02-26 | |
| 2019-01-01 | $9.85M 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |